Presenters:
The understanding of Polycystic Ovarian Syndrome (PCOS) is evolving. The shift toward Polyendocrine Metabolic Ovarian Syndrome (PMOS) moves the conversation beyond the ovaries and recognizes the complex metabolic, endocrine, and neuroendocrine factors involved in this condition.
In “Decoding PMOS: Moving Beyond the Ovaries,” Belmar Pharma Solutions presents an educational webinar featuring Angela DeRosa, DO, MBA, CPE, Medical Director of Belmar Pharma Solutions, and Andi Roths, PharmD, Director of Women’s Health.
From PCOS to PMOS: Why the Name Matters
PMOS is more than an ovarian disorder. Dr. DeRosa and Andi explore how insulin resistance, hyperandrogenism, ovarian and adrenal androgen production, adipose dysfunction, and neuroendocrine signaling can contribute to PMOS.
Dr. DeRosa and Andi also review diagnostic criteria, PMOS phenotypes, metabolic risk factors, and screening considerations, including why providers should look beyond ovarian morphology when evaluating patients.
A Systemic Approach to PMOS Therapies
Because PMOS can affect reproductive, metabolic, dermatologic, and psychological health, therapy requires an individualized, multi-system approach. This webinar examines strategies for addressing menstrual irregularity, hyperandrogenic symptoms, insulin resistance, fertility concerns, and long-term metabolic risks.
Dr. DeRosa and Andi discuss therapy options, including hormonal contraception, metformin, GLP-1 medications, spironolactone, inositol, and other supportive therapies. They also explore customized compounded medications, including specialized metformin dosing and topical formulations for PMOS-related hair and skin concerns.
Watch Decoding PMOS: Moving Beyond the Ovaries
This webinar is intended for healthcare providers who want to better understand the evolving approach to PMOS diagnosis and treatment.
Fill out the form below to access the webinar replay, and learn how looking beyond the ovaries can provide a more complete perspective on PMOS and patient care.
